

# Ingrid van der Mei

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1921160/publications.pdf>

Version: 2024-02-01

170  
papers

8,654  
citations

57719

44  
h-index

49868

87  
g-index

171  
all docs

171  
docs citations

171  
times ranked

7713  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1816-1821.	1.4	965
2	Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1132-1141.	0.9	556
3	Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. <i>BMJ: British Medical Journal</i> , 2003, 327, 316-0.	2.4	457
4	Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. <i>Annals of Neurology</i> , 2010, 68, 193-203.	2.8	388
5	Sun exposure and vitamin D are independent risk factors for CNS demyelination. <i>Neurology</i> , 2011, 76, 540-548.	1.5	324
6	Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. <i>Journal of Neurology</i> , 2007, 254, 581-590.	1.8	285
7	Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 217-224.	1.4	234
8	The High Prevalence of Vitamin D Insufficiency across Australian Populations Is Only Partly Explained by Season and Latitude. <i>Environmental Health Perspectives</i> , 2007, 115, 1132-1139.	2.8	198
9	Regional Variation in Multiple Sclerosis Prevalence in Australia and Its Association with Ambient Ultraviolet Radiation. <i>Neuroepidemiology</i> , 2001, 20, 168-174.	1.1	195
10	UVR, Vitamin D and Three Autoimmune Diseases—Multiple Sclerosis, Type 1 Diabetes, Rheumatoid Arthritis. <i>Photochemistry and Photobiology</i> , 2005, 81, 1267.	1.3	186
11	Ultraviolet radiation and autoimmune disease: insights from epidemiological research. <i>Toxicology</i> , 2002, 181-182, 71-78.	2.0	175
12	Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e1870-e1885.	1.5	168
13	Monthly Ambient Sunlight, Infections and Relapse Rates in Multiple Sclerosis. <i>Neuroepidemiology</i> , 2008, 31, 271-279.	1.1	142
14	Exposure to Infant Siblings During Early Life and Risk of Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 463.	3.8	137
15	Combined effects of smoking, anti-EBNA antibodies, and <i>HLA-DRB1*1501</i> on multiple sclerosis risk. <i>Neurology</i> , 2010, 74, 1365-1371.	1.5	124
16	An adverse lipid profile is associated with disability and progression in disability, in people with MS. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1737-1744.	1.4	123
17	Offspring number, pregnancy, and risk of a first clinical demyelinating event. <i>Neurology</i> , 2012, 78, 867-874.	1.5	122
18	Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. <i>Journal of Neurology</i> , 2009, 256, 577-585.	1.8	117

#	ARTICLE	IF	CITATIONS
19	Validity and Reliability of Adult Recall of Past Sun Exposure in a Case-Control Study of Multiple Sclerosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1538-1544.	1.1	100
20	Genetic Dissection of the Human Leukocyte Antigen Region by Use of Haplotypes of Tasmanians with Multiple Sclerosis. <i>American Journal of Human Genetics</i> , 2002, 70, 1125-1137.	2.6	93
21	Interferon- $\beta$ and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. <i>Neurology</i> , 2012, 79, 254-260.	1.5	90
22	The Contributions of Solar Ultraviolet Radiation Exposure and Other Determinants to Serum 25-Hydroxyvitamin D Concentrations in Australian Adults: The AusD Study. <i>American Journal of Epidemiology</i> , 2014, 179, 864-874.	1.6	84
23	Past environmental sun exposure and risk of multiple sclerosis: a role for the Cdx-2 Vitamin D receptor variant in this interaction. <i>Multiple Sclerosis Journal</i> , 2009, 15, 563-570.	1.4	82
24	Latitudinal variation in incidence and type of first central nervous system demyelinating events. <i>Multiple Sclerosis Journal</i> , 2010, 16, 398-405.	1.4	80
25	Higher intake of omega-3 polyunsaturated fatty acids is associated with a decreased risk of a first clinical diagnosis of central nervous system demyelination: Results from the Ausimmune Study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 884-892.	1.4	80
26	The role of latitude, ultraviolet radiation exposure and vitamin D in childhood asthma and hayfever: an Australian multicenter study. <i>Pediatric Allergy and Immunology</i> , 2011, 22, 327-333.	1.1	78
27	Vitamin D status: Multifactorial contribution of environment, genes and other factors in healthy Australian adults across a latitude gradient. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 136, 300-308.	1.2	78
28	Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies. <i>Neurology: Genetics</i> , 2016, 2, e87.	0.9	76
29	Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 565-576.	0.9	73
30	Current and past Epstein-Barr virus infection in risk of initial CNS demyelination. <i>Neurology</i> , 2011, 77, 371-379.	1.5	71
31	Vascular comorbidities in the onset and progression of multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2014, 347, 23-33.	0.3	71
32	An adverse lipid profile and increased levels of adiposity significantly predict clinical course after a first demyelinating event. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 395-401.	0.9	71
33	What affects your MS? Responses to an anonymous, Internet-based epidemiological survey. <i>Multiple Sclerosis Journal</i> , 2004, 10, 202-211.	1.4	68
34	Observational analytic studies in multiple sclerosis: controlling bias through study design and conduct. The Australian Multicentre Study of Environment and Immune Function. <i>Multiple Sclerosis Journal</i> , 2007, 13, 827-839.	1.4	68
35	Individual and Joint Action of Environmental Factors and Risk of MS. <i>Neurologic Clinics</i> , 2011, 29, 233-255.	0.8	63
36	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1343-1349.	0.9	63

#	ARTICLE	IF	CITATIONS
37	Population attributable fractions and joint effects of key risk factors for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 461-469.	1.4	59
38	Higher levels of reported sun exposure, and not vitamin D status, are associated with less depressive symptoms and fatigue in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2014, 129, 123-131.	1.0	54
39	Associations between Silicone Skin Cast Score, Cumulative Sun Exposure, and Other Factors in the Ausimmune Study: A Multicenter Australian Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2887-2894.	1.1	52
40	Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 799-806.	1.4	51
41	COVID-19 in people with multiple sclerosis: A global data sharing initiative. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1157-1162.	1.4	50
42	Validation of linear cerebral atrophy markers in multiple sclerosis. <i>Journal of Clinical Neuroscience</i> , 2008, 15, 130-137.	0.8	47
43	Anxiety, depression and fatigue at 5-year review following CNS demyelination. <i>Acta Neurologica Scandinavica</i> , 2016, 134, 403-413.	1.0	47
44	Melanocortin 1 receptor genotype, past environmental sun exposure, and risk of multiple sclerosis. <i>Neurology</i> , 2008, 71, 583-589.	1.5	46
45	Multiple Sclerosis Susceptibility-Associated SNPs Do Not Influence Disease Severity Measures in a Cohort of Australian MS Patients. <i>PLoS ONE</i> , 2010, 5, e10003.	1.1	45
46	Frequency of Comorbidities and Their Association with Clinical Disability and Relapse in Multiple Sclerosis. <i>Neuroepidemiology</i> , 2016, 46, 106-113.	1.1	45
47	Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1655-1664.	1.4	44
48	Trends in the epidemiology of multiple sclerosis in Greater Hobart, Tasmania: 1951 to 2009. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 180-187.	0.9	43
49	Vitamin D and multiple sclerosis. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 634-641.	0.8	41
50	Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1200-1207.	0.9	41
51	Estimating MS-related work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 994-1004.	1.4	41
52	Heterogeneity at the HLA-DRB1 allelic variation locus does not influence multiple sclerosis disease severity, brain atrophy or cognition. <i>Multiple Sclerosis Journal</i> , 2011, 17, 344-352.	1.4	40
53	Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy. <i>Neurology</i> , 2009, 73, 1018-1025.	1.5	39
54	The co-occurrence of multiple sclerosis and type 1 diabetes: Shared aetiologic features and clinical implication for MS aetiology. <i>Journal of the Neurological Sciences</i> , 2015, 348, 126-131.	0.3	39

#	ARTICLE	IF	CITATIONS
55	Waterpipe smoking associated with multiple sclerosis: A population-based incident caseâ€“control study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1328-1335.	1.4	39
56	Role of genetic susceptibility variants in predicting clinical course in multiple sclerosis: a cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1204-1211.	0.9	38
57	The role of epidemiology in MS research: Past successes, current challenges and future potential. <i>Multiple Sclerosis Journal</i> , 2015, 21, 969-977.	1.4	37
58	The genetics of multiple sclerosis. <i>Practical Neurology</i> , 2012, 12, 279-288.	0.5	36
59	A Higher Mediterranean Diet Score, Including Unprocessed Red Meat, Is Associated with Reduced Risk of Central Nervous System Demyelination in a Case-Control Study of Australian Adults. <i>Journal of Nutrition</i> , 2019, 149, 1385-1392.	1.3	36
60	Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1209-1213.	0.9	35
61	Asthma onset prior to multiple sclerosis and the contribution of sibling exposure in early life. <i>Clinical and Experimental Immunology</i> , 2006, 146, 463-470.	1.1	34
62	Adverse lipid profile is not associated with relapse risk in MS: Results from an observational cohort study. <i>Journal of the Neurological Sciences</i> , 2014, 340, 230-232.	0.3	33
63	Novel modulating effects of PKC family genes on the relationship between serum vitamin D and relapse in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 399-404.	0.9	32
64	The physical anthropometry, lifestyle habits and blood pressure of people presenting with a first clinical demyelinating event compared to controls: The Ausimmune study. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1717-1725.	1.4	30
65	Sun Exposure across the Life Course Significantly Modulates Early Multiple Sclerosis Clinical Course. <i>Frontiers in Neurology</i> , 2018, 9, 16.	1.1	30
66	Change in multiple sclerosis prevalence over time in Australia 2010â€“2017 utilising disease-modifying therapy prescription data. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1315-1328.	1.4	30
67	Dietary patterns and associations with health outcomes in Australian people with multiple sclerosis. <i>European Journal of Clinical Nutrition</i> , 2021, 75, 1506-1514.	1.3	30
68	The potential role of epigenetic modifications in the heritability of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 135-140.	1.4	29
69	The relationship between ambient ultraviolet radiation (UVR) and objectively measured personal UVR exposure dose is modified by season and latitude. <i>Photochemical and Photobiological Sciences</i> , 2014, 13, 1711-1718.	1.6	28
70	The impact of multiple sclerosis severity on health state utility values: Evidence from Australia. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1157-1166.	1.4	28
71	Stimulated PBMC-produced IFN- $\gamma$ and TNF- $\alpha$ are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 200-207.	0.9	27
72	EBV & HHV6 reactivation is infrequent and not associated with MS clinical course. <i>Acta Neurologica Scandinavica</i> , 2014, 130, 328-337.	1.0	26

#	ARTICLE	IF	CITATIONS
73	Human leukocyte antigen-DR15, low infant sibling exposure and multiple sclerosis: Gene-environment interaction. <i>Annals of Neurology</i> , 2010, 67, 261-265.	2.8	24
74	Association between human herpesvirus & human endogenous retrovirus and MS onset & progression. <i>Journal of the Neurological Sciences</i> , 2017, 372, 239-249.	0.3	24
75	The AusD Study: A Population-based Study of the Determinants of Serum 25-Hydroxyvitamin D Concentration Across a Broad Latitude Range. <i>American Journal of Epidemiology</i> , 2013, 177, 894-903.	1.6	23
76	Association between multiple sclerosis risk-associated SNPs and relapse and disability - a prospective cohort study. <i>Multiple Sclerosis Journal</i> , 2014, 20, 313-321.	1.4	23
77	Misclassification due to body hair and seasonal variation on melanin density estimates for skin type using spectrophotometry. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2002, 68, 45-52.	1.7	22
78	The effect of season on cytokine expression in multiple sclerosis and healthy subjects. <i>Journal of Neuroimmunology</i> , 2007, 188, 181-186.	1.1	22
79	Sun Exposure over a Lifetime in Australian Adults from Latitudinally Diverse Regions. <i>Photochemistry and Photobiology</i> , 2013, 89, 737-744.	1.3	22
80	Cumulative risks and cessation of exclusive breast feeding: Australian cross-sectional survey. <i>Archives of Disease in Childhood</i> , 2015, 100, 863-868.	1.0	22
81	Lifestyle factors and multiple sclerosis: A population-based incident case-control study. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 128-133.	0.9	22
82	Role of environmental factors in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 1389-1408.	1.4	22
83	Weekend personal ultraviolet radiation exposure in four cities in Australia: Influence of temperature, humidity and ambient ultraviolet radiation. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2015, 143, 74-81.	1.7	21
84	Genetic variation in the gene <i>LRP2</i> increases relapse risk in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 864-868.	0.9	21
85	Patient-reported outcomes are worse for progressive-onset multiple sclerosis than relapse-onset multiple sclerosis, particularly early in the disease process. <i>European Journal of Neurology</i> , 2019, 26, 155-161.	1.7	20
86	Feelings of depression, pain and walking difficulties have the largest impact on the quality of life of people with multiple sclerosis, irrespective of clinical phenotype. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1262-1275.	1.4	20
87	Common genetic variation within miR-146a predicts disease onset and relapse in multiple sclerosis. <i>Neurological Sciences</i> , 2018, 39, 297-304.	0.9	19
88	Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia. <i>Multiple Sclerosis Journal</i> , 2020, 26, 411-420.	1.4	18
89	The Role of Vitamin D in Multiple Sclerosis: Biology and Biochemistry, Epidemiology and Potential Roles in Treatment. <i>Medicinal Chemistry</i> , 2018, 14, 129-143.	0.7	18
90	Contact dermatitis in <i>Alstroemeria</i> workers. <i>Occupational Medicine</i> , 1998, 48, 397-404.	0.8	17

#	ARTICLE	IF	CITATIONS
91	Assessing interactions between HLA-DRB1*15 and infectious mononucleosis on the risk of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1355-1358.	1.4	17
92	Occupational Exposure and Risk of Central Nervous System Demyelination. <i>American Journal of Epidemiology</i> , 2013, 177, 954-961.	1.6	17
93	Early-life hygiene-related factors affect risk of central nervous system demyelination and asthma differentially. <i>Clinical and Experimental Immunology</i> , 2013, 172, 466-474.	1.1	17
94	Variation within <i>MBP</i> gene predicts disease course in multiple sclerosis. <i>Brain and Behavior</i> , 2017, 7, e00670.	1.0	17
95	Closing the gap: Longitudinal changes in employment for Australians with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1415-1423.	1.4	17
96	Modifiable factors associated with depression and anxiety in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 204-211.	1.0	16
97	Comorbidities are prevalent and detrimental for employment outcomes in people of working age with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1550-1559.	1.4	16
98	Physical activity, sitting time and exercise types, and associations with symptoms in Australian people with multiple sclerosis. <i>Disability and Rehabilitation</i> , 2022, 44, 1380-1388.	0.9	16
99	Investigating the patterns and determinants of seasonal variation in vitamin D status in Australian adults: the Seasonal D Cohort Study. <i>BMC Public Health</i> , 2016, 16, 892.	1.2	15
100	The multiple sclerosis risk allele within the <i>AHI1</i> gene is associated with relapses in children and adults. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 161-165.	0.9	15
101	Higher fish consumption and lower risk of central nervous system demyelination. <i>European Journal of Clinical Nutrition</i> , 2020, 74, 818-824.	1.3	15
102	The increasing economic burden of multiple sclerosis by disability severity in Australia in 2017: Results from updated and detailed data on types of costs. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102247.	0.9	15
103	Adherence to <i>MRI</i> protocol consensus guidelines in multiple sclerosis: An Australian multicentre study. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2012, 56, 594-598.	0.9	14
104	Modulating effects of <i>WT1</i> on interferon- $\gamma$ -vitamin D association in MS. <i>Acta Neurologica Scandinavica</i> , 2015, 131, 231-239.	1.0	14
105	Stressful life events and the risk of initial central nervous system demyelination. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1000-1007.	1.4	14
106	Higher Non-processed Red Meat Consumption Is Associated With a Reduced Risk of Central Nervous System Demyelination. <i>Frontiers in Neurology</i> , 2019, 10, 125.	1.1	14
107	Validation of "10 MS symptom scores in the Australian multiple sclerosis longitudinal study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101895.	0.9	14
108	Vitamin D and the musculoskeletal health of older adults. <i>Australian Family Physician</i> , 2012, 41, 92-9.	0.5	13

#	ARTICLE	IF	CITATIONS
109	Measuring the health-related quality of life in Australians with multiple sclerosis using the assessment of quality of life-8-dimension (AQoL-8D) multi-attribute utility instrument. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102358.	0.9	12
110	Weekly cholecalciferol supplementation results in significant reductions in infection risk among the vitamin D deficient: results from the CIPRIS pilot RCT. <i>BMC Nutrition</i> , 2015, 1, .	0.6	11
111	The role of nutritional factors during adolescence in multiple sclerosis onset: a population-based incident case-control study. <i>Nutritional Neuroscience</i> , 2019, 24, 1-8.	1.5	11
112	The effect of emerging nutraceutical interventions for clinical and biological outcomes in multiple sclerosis: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101486.	0.9	11
113	Estimating the relative contribution of comorbidities in predicting health-related quality of life of people with multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 569-581.	1.8	11
114	Change and onset-type differences in the prevalence of comorbidities in people with multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 602-612.	1.8	11
115	Increasing prevalence of primary biliary cholangitis in Victoria, Australia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 673-679.	1.4	10
116	Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1765-1774.	1.4	10
117	High Prudent diet factor score predicts lower relapse hazard in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1112-1124.	1.4	10
118	Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103561.	0.9	10
119	Increasing incidence and prevalence of multiple sclerosis in the Greater Hobart cohort of Tasmania, Australia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 723-731.	0.9	10
120	Vitamin D deficiency in Tasmania: a whole of life perspective. <i>Internal Medicine Journal</i> , 2012, 42, 1137-1144.	0.5	9
121	Work productivity trajectories of Australians living with multiple sclerosis: A group-based modelling approach. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103131.	0.9	9
122	CTLA-4 and multiple sclerosis: The A49G single nucleotide polymorphism shows no association with multiple sclerosis in a Southern Australian population. <i>Journal of Neuroimmunology</i> , 2008, 196, 139-142.	1.1	8
123	Association between exposure to farm animals and pets and risk of Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 10, 53-56.	0.9	8
124	Onset Symptoms, Tobacco Smoking, and Progressive-Onset Phenotype Are Associated With a Delayed Onset of Multiple Sclerosis, and Marijuana Use With an Earlier Onset. <i>Frontiers in Neurology</i> , 2018, 9, 418.	1.1	8
125	Meta-Analyses to Investigate Gene-Environment Interactions in Neuroepidemiology. <i>Neuroepidemiology</i> , 2014, 42, 39-49.	1.1	7
126	Predictors of Beagley-Gibson skin cast grade in older adults. <i>Skin Research and Technology</i> , 2017, 23, 235-242.	0.8	7



#	ARTICLE	IF	CITATIONS
127	Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1800-1808.	1.4	7
128	Comorbidities contribute substantially to the severity of common multiple sclerosis symptoms. <i>Journal of Neurology</i> , 2021, 268, 559-568.	1.8	7
129	Developing a clinical“environmental”genotypic prognostic index for relapsing-onset multiple sclerosis and clinically isolated syndrome. <i>Brain Communications</i> , 2021, 3, fcab288.	1.5	7
130	Birth order, infection in early life, and multiple sclerosis. <i>Lancet Neurology</i> , The, 2005, 4, 793-794.	4.9	6
131	Measuring Exposure to Solar Ultraviolet Radiation Using a Dosimetric Technique: Understanding Participant Compliance Issues. <i>Photochemistry and Photobiology</i> , 2014, 90, 919-924.	1.3	6
132	Midsagittal corpus callosum area and conversion to multiple sclerosis after clinically isolated syndrome: A multicentre Australian cohort study. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 453-460.	0.9	6
133	Polymorphism in the serotonin transporter gene polymorphisms ( <i>5-HTTLPR</i> ) modifies the association between significant life events and depression in people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 848-855.	1.4	6
134	Risk factors for leaving employment due to multiple sclerosis and changes in risk over the past decades: Using competing risk survival analysis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1250-1261.	1.4	6
135	Comorbidity patterns in people with multiple sclerosis: A latent class analysis of the Australian Multiple Sclerosis Longitudinal Study. <i>European Journal of Neurology</i> , 2021, 28, 2269-2279.	1.7	6
136	The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 831-841.	1.4	6
137	Genetic variation in PBMC-produced IFN- $\gamma$ and TNF- $\alpha$ associations with relapse in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2015, 349, 40-44.	0.3	5
138	Development and psychometric properties of the Multiple Sclerosis Knowledge Assessment Scale: Rasch analysis of a novel tool for evaluating MS knowledge. <i>Multiple Sclerosis Journal</i> , 2021, 27, 767-777.	1.4	5
139	A proinflammatory diet is associated with an increased likelihood of first clinical diagnosis of central nervous system demyelination in women. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103428.	0.9	5
140	Psychological impacts of COVID-19 pandemic on individuals living with multiple sclerosis: A rapid systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103562.	0.9	5
141	Role of vitamin D in multiple sclerosis: implications for disease management. <i>Neurodegenerative Disease Management</i> , 2011, 1, 523-536.	1.2	4
142	Oral health and behaviours of people living with Multiple Sclerosis in Australia. <i>Community Dentistry and Oral Epidemiology</i> , 2019, 47, 201-209.	0.9	4
143	Identification of a Latitude Gradient in the Prevalence of Primary Biliary Cholangitis. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00357.	1.3	4
144	Omega-3 Index, fish consumption, use of fish oil supplements and first clinical diagnosis of central nervous system demyelination. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103210.	0.9	4

#	ARTICLE	IF	CITATIONS
145	PAST SUN EXPOSURE, SKIN PHENOTYPE AND RISK OF MULTIPLE SCLEROSIS. <i>Epidemiology</i> , 2003, 14, S113-S114. 1.2		4
146	Evaluating the impact of the Understanding Multiple Sclerosis online course on participant MS knowledge, health literacy, resilience, self-efficacy, quality of life, and MS symptom severity. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103717. 0.9		4
147	Self-Reported Changes in Sun-Protection Behaviors at Different Latitudes in Australia. <i>Photochemistry and Photobiology</i> , 2016, 92, 495-502. 1.3		3
148	Validation of Sun Exposure Reported Annually Against Interim Self-report and Daily Sun Diaries. <i>Photochemistry and Photobiology</i> , 2017, 93, 1294-1302. 1.3		3
149	Association between MS-related knowledge, health literacy, self-efficacy, resilience, and quality of life in a large cohort of MS community members: A cross-sectional study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103158. 0.9		3
150	The Multiple Sclerosis Data Alliance Catalogue. <i>International Journal of MS Care</i> , 2021, 23, 261-268. 0.4		3
151	Physical activity participation in Australians with multiple sclerosis: associations with geographical remoteness. <i>Disability and Rehabilitation</i> , 2023, 45, 1969-1974. 0.9		3
152	Exposure to Infant Siblings During Early Life and Risk of Multiple Sclerosis—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 2089. 3.8		2
153	Environmental and genetic determinants of two vitamin D metabolites in healthy Australian children. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2017, 30, 531-541. 0.4		2
154	Vitamin D deficiency is an etiological factor for MS — Commentary. <i>Multiple Sclerosis Journal</i> , 2019, 25, 641-643. 1.4		2
155	Impact of remoteness on patient outcomes for people with multiple sclerosis in Australia. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103208. 0.9		2
156	Vitamin D metabolites and risk of first clinical diagnosis of central nervous system demyelination. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2022, 218, 106060. 1.2		2
157	Long-term trajectories of employment status, workhours and disability support pension status, after a first episode of CNS demyelination. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1793-1807. 1.4		2
158	Lipids in multiple sclerosis: adverse lipid profiles, disability and disease progression. <i>Clinical Lipidology</i> , 2014, 9, 473-475. 0.4		1
159	Synergetic and antagonistic effects of combined calcitriol and interferon- $\beta$ treatment on cytokine production by stimulated PBMCs. <i>Journal of Neuroimmunology</i> , 2016, 297, 148-155. 1.1		1
160	Assessing the consistency and validity of self-reported year of diagnosis among participants in a longitudinal study of people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102755. 0.9		1
161	Does health-related quality of life differ between people with relapse onset and progressive onset Multiple Sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103138. 0.9		1
162	Response to Attarian regarding article. <i>Acta Neurologica Scandinavica</i> , 2017, 135, 382-382. 1.0		0

#	ARTICLE	IF	CITATIONS
163	197Assessment of Depression, Anxiety and Fatigue in relation to diet quality in Multiple Sclerosis. International Journal of Epidemiology, 2021, 50, .	0.9	0
164	100Identification of a latitude gradient in the prevalence of Primary Biliary Cholangitis in Australia. International Journal of Epidemiology, 2021, 50, .	0.9	0
165	937Rasch analysis of the Health Literacy Questionnaire in the Understanding Multiple Sclerosis online course cohort. International Journal of Epidemiology, 2021, 50, .	0.9	0
166	1256Psychological impacts of COVID-19 pandemic on individuals living with multiple sclerosis: a rapid systematic review. International Journal of Epidemiology, 2021, 50, .	0.9	0
167	1234Smoking, infectious mononucleosis, early-life exposures and risk of progressive-onset Multiple Sclerosis: a case-control study. International Journal of Epidemiology, 2021, 50, .	0.9	0
168	101Pre-onset sun exposure significantly associated with risk of primary biliary cirrhosis. International Journal of Epidemiology, 2021, 50, .	0.9	0
169	99Increasing prevalence of primary biliary cholangitis in Victoria, Australia. International Journal of Epidemiology, 2021, 50, .	0.9	0
170	Estimating the impact of work difficulties, work self-efficacy and work psychological safety on MS-related work productivity loss. Multiple Sclerosis Journal, 0, , 135245852210975.	1.4	0